Antibody therapeutics company Lassen Therapeutics has closed an oversubscribed $85 million Series B financing. The proceeds will fund a Phase II study in thyroid eye disease (TED) with the company’s monoclonal antibody LASN01 and the continued development of LASN500 for cancer. The clinical programme for LASN01 is focused primarily in TED with a cohort in […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!